Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.40 |
| ▸ | CES1 | P23141 | 2/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.36 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.36 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.34 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | XBP1 | P17861 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.32 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2944822 | 0.94 | CES2 (0.47) | CES2CES1PRSS1PRSS2PRSS3 | |
| SCHEMBL2945431 | 0.89 | CES2 (0.39) | CES2CES1GPR52CYP2D6MAPK1 | |
| SCHEMBL4318712 | 0.86 | CES2 (0.36) | CES2CES1CNR2GPR52MAPK1 | |
| SCHEMBL4318711 | 0.86 | CES2 (0.36) | CES2CES1CNR2GPR52MAPK1 | |
| SCHEMBL2946902 | 0.86 | FFAR1 (0.40) | CES2CES1GPR52 | |
| SCHEMBL2942825 | 0.84 | ALDH1A1 (0.42) | CES2CES1CYP2D6NPC1MAPT | |
| SCHEMBL4323510 | 0.84 | CES2 (0.46) | CES2CES1CNR2MEN1KCNK3 | |
| SCHEMBL2944394 | 0.82 | CES2 (0.41) | CES2CES1MAPK1MAPTSMN1; SMN2 | |
| SCHEMBL2948367 | 0.81 | MAPK14 (0.39) | CES2CES1CYP2D6TSHR | |
| SCHEMBL2947996 | 0.81 | MAPK14 (0.39) | CES2CES1CYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076367-B2 | Benzimidazolylidene propane-1,3-dione derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2011-12-13 | — | — | US | disclosed |
| US-20100173946-A1 | BENZIMIDAZOLYLIDENE PROPANE-1,3-DIONE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2010-07-08 | — | — | US | disclosed |
| US-7709519-B2 | Benzimidazolylidene propane-1,3 dione derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2010-05-04 | — | — | US | disclosed |
| US-20090018177-A1 | Propane-1,3-Dione Derivative or Salt Thereof | ASTELLAS PHARMA INC. (JP) | 2009-01-15 | — | — | US | disclosed |
| EP-1752452-A9 | PROPANE-1,3-DIONE DERIVATIVE OR ITS SALT | Astellas Pharma Inc. (JP) | 2007-12-12 | — | — | EP | disclosed |
| EP-1752452-A1 | PROPANE-1,3-DIONE DERIVATIVE OR ITS SALT | Astellas Pharma Inc. (JP) | 2007-02-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018177-A1 | Propane-1,3-Dione Derivative or Salt Thereof | GPER1, GNRHR, AR | CES2 4083/4885CES1 1983/4885PRSS1 523/4885 |
| US-20100173946-A1 | BENZIMIDAZOLYLIDENE PROPANE-1,3-DIONE DERIVATIVE OR SALT THEREOF | GPER1, GNRHR, AR | CES2 4228/4885CES1 2243/4885PRSS1 637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.